Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassi
Go back to Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassi| Celgene Corp. (NASDAQ: CELG) | Delayed: 108.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.24 | 52 Week High | $127.00 | |||
| Open | $7.85 | 52 Week Low | $93.05 | |||
| Day High | $108.24 | P/E | 32.12 | |||
| Day Low | $108.24 | EPS | $3.37 | |||
| Volume | 0 | |||||
